Table I.
Patient's characteristics (n=184).
| Variable | Value |
|---|---|
| Age, years; median (range) | 64.0 (50–91) |
| Body mass index, kg/m2; median (range) | 23.6 (14.6–38.8) |
| Histology, n (%) | |
| Invasive ductal carcinoma | 164 (89.1) |
| Invasive lobular carcinoma | 4 (2.2) |
| Other | 16 (8.7) |
| pT stage, n (%) | |
| T1 | 130 (70.7) |
| T2 | 49 (26.6) |
| T3 | 1 (0.5) |
| T4 | 4 (2.2) |
| Nodal status, n (%) | |
| Negative | 144 (78.3) |
| Positive | 40 (21.7) |
| Nuclear grade, n (%) | |
| I | 25 (13.6) |
| II | 132 (71.7) |
| III | 22 (12.0) |
| Unknown | 5 (2.7) |
| Lymphovascular invasion, n (%) | |
| Negative | 30 (16.3) |
| Positive | 154 (83.7) |
| Progesterone receptor, n (%) | |
| Negative | 30 (16.3) |
| Positive | 154 (83.7) |
| Ki-67 labeling index, %; median (range) | 16.3 (0.3–60.0) |
| Type of surgery, n (%) | |
| Breast-conserving surgery | 137 (74.5) |
| Modified radical mastectomy | 47 (25.5) |
| Endocrine therapy, n (%) | |
| Anastrozole | 96 (52.2) |
| Letrozole | 84 (45.7) |
| Exemestane | 4 (2.1) |
| Chemotherapy, n (%) | |
| Yes | 53 (28.8) |
| No | 131 (71.2) |
| Recurrence, n (%) | |
| Local recurrence | 5 (2.7) |
| Distant metastasis | 11 (6.0) |